NAGE vs. ADMA, PCVX, ZLAB, PTCT, RYTM, CYTK, ACAD, KRYS, MRUS, and RNA
Should you be buying Niagen Bioscience stock or one of its competitors? The main competitors of Niagen Bioscience include ADMA Biologics (ADMA), Vaxcyte (PCVX), Zai Lab (ZLAB), PTC Therapeutics (PTCT), Rhythm Pharmaceuticals (RYTM), Cytokinetics (CYTK), ACADIA Pharmaceuticals (ACAD), Krystal Biotech (KRYS), Merus (MRUS), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry.
Niagen Bioscience vs. Its Competitors
Niagen Bioscience (NASDAQ:NAGE) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, risk and dividends.
15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 9.4% of Niagen Bioscience shares are held by company insiders. Comparatively, 3.7% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
ADMA Biologics has a net margin of 45.01% compared to Niagen Bioscience's net margin of 13.07%. ADMA Biologics' return on equity of 47.16% beat Niagen Bioscience's return on equity.
Niagen Bioscience has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.
ADMA Biologics received 409 more outperform votes than Niagen Bioscience when rated by MarketBeat users. However, 100.00% of users gave Niagen Bioscience an outperform vote while only 72.05% of users gave ADMA Biologics an outperform vote.
Niagen Bioscience currently has a consensus target price of $19.50, suggesting a potential upside of 38.00%. ADMA Biologics has a consensus target price of $27.67, suggesting a potential upside of 55.00%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts plainly believe ADMA Biologics is more favorable than Niagen Bioscience.
ADMA Biologics has higher revenue and earnings than Niagen Bioscience. ADMA Biologics is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.
In the previous week, Niagen Bioscience had 1 more articles in the media than ADMA Biologics. MarketBeat recorded 8 mentions for Niagen Bioscience and 7 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 0.56 beat Niagen Bioscience's score of 0.12 indicating that ADMA Biologics is being referred to more favorably in the news media.
Summary
ADMA Biologics beats Niagen Bioscience on 12 of the 18 factors compared between the two stocks.
Get Niagen Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAGE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Niagen Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:NAGE) was last updated on 6/25/2025 by MarketBeat.com Staff
Buy NAGE Stock Free NAGE Stock Alerts